Antiparkinson agents
Staal-Schreinemachers, A.L.; Lakke, J.P.
Nederlands Tijdschrift Voor Geneeskunde 131(6): 228-230
1987
ISSN/ISBN: 0028-2162 PMID: 3561558 Document Number: 288757
Document emailed within 1 workday
Related Documents
Veje, V.O. 1981: Drug information: antiparkinson agents. I. Anticholinergic agents Sygeplejersken 81(34): 11Delwaide, P.J. 1996: L-dopa and antiparkinson agents Revue Medicale de Liege 51(1): 61-64
Veje, J.O. 1981: Drug information: antiparkinson agents Sygeplejersken 81(32): 10
Kurako, I.L.; Volianskiĭ, V.E.; Fadeev, S.M. 1981: Therapeutic effectiveness of modern antiparkinson agents Vrachebnoe Delo 2: 7-11
Occelli, E.; Fontanella, L.; Testa, E. 1977: Bicyclic analogs of piperazine. XII. (1) - Synthesis of 3,8-diazabicyclo/3,2,1/octanes as potential antiparkinson agents Il Farmaco; Edizione Scientifica 32(4): 237-247
Gjerden, P.; Slørdal, L. 1998: Clinical pharmacology of anticholinergic antiparkinson agents. a review with emphasis on acute toxicity Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 118(1): 53-55
Estler, C.J. 1984: Drug interactions of central nervous system active drugs. 3: Drug interactions of anticonvulsants and antiparkinson agents Fortschritte der Medizin 102(6): 129-132
Horsmans, Y.; Larrey, D.; Pessayre, D.; Benhamou, J.P. 1990: Hepatotoxicity of antimicrobial agents. II: Urinary antiseptics, antitubercular agents, antiparasitic agents, antifungal agents, antiviral agents Gastroenterologie Clinique et Biologique 14(12): 919-924
Val'dman, E.A.; Voronina, T.A.; Nerobkova, L.N. 1999: The antiparkinson activity of a new adamantane derivative Eksperimental'naia i Klinicheskaia Farmakologiia 62(4): 3-6
Retterstol, N. 1973: Antiparkinson drugs--abuse among youth Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 93(31): 2332
Stock, B.; Spiteller, G. 1979: Metabolism of antiparkinson drugs. An example of competitive hydroxylation Arzneimittel-Forschung 29(4): 610-615
Youdim, M.B. 1990: Inhibitors of dopamine inactivating systems as antiparkinson drugs Advances in Neurology 53: 483-488
David, J.; Kaul, C.L.; Grewal, R.S. 1979: Pharmacological & biochemical characterization of antiparkinson drugs in reserpinized mice Indian Journal of Experimental Biology 17(8): 760-764
Ben Hadj Ali, B.; Dogui, M.; Ben Ammou, S.; Lôo, H. 1995: Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal L'Encephale 21(3): 209-215
Martínez-Suárez, M.M.; Blázquez-Menes, B. 2000: Estimation of the prevalence of Parkinson's disease in Asturia, Spain. a pharmacoepidemiological study of the consumption of antiparkinson drugs Revista de Neurologia 31(11): 1001-1006
Tadori, Y.; Kobayashi, H. 2014: The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors Nihon Shinkei Seishin Yakurigaku Zasshi 34(5-6): 127-132
Sigwald, J.; Raymondeaud, C.; Piot, C. 1973: Method for appraisal and measurement of extrapyramidal symptoms and signs. Clinical evaluation of Parkinsonism. Value in the evaluation of severeness, in the estimation of the evolutive potential, in the appreciation as strict as possible of the effectiveness of antiparkinson therapy La Semaine des Hopitaux: Organe Fonde Par l'Association d'Enseignement Medical des Hopitaux de Paris 49(10): 693-704
Lumholtz, I.B. 1981: Drug information: agents for the treatment of arrhythmias. Therapeutic main group: anti-arrhythmia agents. 16. (3). Anti-arrhythmia agents with action on ventricular arrhythmias Sygeplejersken 81(2): 15
Nightengale, B.S.; Crumly, J.M.; Liao, J.; Lawrence, B.J.; Jacobs, E.W. 1998: Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone Psychopharmacology Bulletin 34(3): 373-382
Ohata, K.; Kohno, S. 1987: Progress of therapeutic agents for asthma--3) Trends in the development of leukotriene inhibitory agents Nihon Rinsho. Japanese Journal of Clinical Medicine 45(8): 1843-1852